Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (1): 30-35    DOI: 10.31083/j.ejgo.2020.01.4788
Original Research Previous articles | Next articles
Combined measurement of miRNA-183, HE4, and CA-125 increases diagnostic efficiency for ovarian cancer
J. Liang1, 4, †, X. Yang2, †, L. Liu3, †, L. Qiao4, P. Peng1, 4, J. Zhou1, 2, *()
1 Department of TCM Gynaecology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China
2 Cancer Research Institute, Southern Medical University, Guangzhou, China
3 Department of Gynaecology, The Third Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Zhuzhou, China
4 Department of Gynaecology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China
Download:  PDF(975KB)  ( 100 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: This study aimed to determine the role of miR-205, miR-182, and miR-183 expression in the serum of ovarian cancer patients in the early diagnosis of ovarian cancer. Materials and Methods: The expression of miR-205, miR-182, miR-183, CA-125, and HE4 was detected in the sera of 101 patients with ovarian cancer, 50 patients with benign ovarian diseases, and 50 healthy volunteers. The results were validated in 98 patients with ovarian cancer, 50 patients with benign ovarian diseases, and 53 healthy volunteers. The expression of miR-205, miR-182, miR-183, CA-125, and HE4 was subjected to ROC analysis and binary logistic regression analysis. Results: The sensitivity of miR-182 and CA-125 was highest (0.901% and 0.832, respectively), but the specificity was low (both 0.27) in the early diagnosis of ovarian cancer. HE4 had the highest specificity in the early diagnosis of ovarian cancer. The sensitivity, specificity, and AUC of HE4 were 0.842, 0.81, and 0.847, respectively. Binary logistic regression analysis showed that three variables were suitable for the diagnostic model: Y=Logit(P)=-5.457+5.365*miR183+0.019*HE4+0.004*CA125. Based on the diagnostic model, ROC analysis showed that the sensitivity, specificity, and AUC were 0.97, 0.85, and 0.951, respectively. Statistical validation showed that the sensitivity, specificity and AUC were 0.941, 0.86, and 0.951, respectively. Conclusion: miR-183 has high specificity and sensitivity in the diagnosis of ovarian cancer. Measurement of miR-183 combined with HE4 and CA-125 is of value for the early diagnosis and evaluation of ovarian cancer.
Key words:  miRNA-183      HE4      CA-125      Ovarian cancer     
Published:  15 February 2020     
*Corresponding Author(s):  JIANLONG ZHOU     E-mail:  303050757@qq.com
About author:  † Contributed equally.

Cite this article: 

J. Liang, X. Yang, L. Liu, L. Qiao, P. Peng, J. Zhou. Combined measurement of miRNA-183, HE4, and CA-125 increases diagnostic efficiency for ovarian cancer. European Journal of Gynaecological Oncology, 2020, 41(1): 30-35.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.01.4788     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I1/30

[1] Siegel R., Naishadham D., Jemal A.: "Cancer statistics, 2013". CA Cancer J. Clin., 2013, 63, 11.
[2] Foley O.W., Rauh-Hain J.A., del Carmen M.G.: "Recurrent epithelial ovarian cancer: an update on treatment". Oncology, 2013, 27, 288.
[3] Hall M., Gourley C., McNeish I., Ledermann J., Gore M., Jayson G., et al.: "Targeted anti-vascular therapies for ovarian cancer: current evidence". Br. J. Cancer, 2013, 108, 250.
[4] Bian J., Li B., Kou X.J., Liu T.Z., Ming L.: "Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer". Asian Pac. J. Cancer Prev., 2013, 14, 6241.
[5] Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., Takeshita H., Kosuga T., et al.: "Circulating microRNAs in plasma of patients with gastric cancers". Br. J. Cancer, 2010, 102, 1174.
[6] Li B.S., Zhao Y.L., Guo G., Li W., Zhu E.D., Luo X., et al.: "Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection". PLoS One, 2012, 7, 41629.
[7] Chen H.X., Zhang L., Zhang L.L., Du J., Wang H.Y., Wang B.: "MicroRNA- 183 correlates cancer prognosis, regulates cancer proliferation and bufalin sensitivity in epithelial ovarian caner". Am. J. Transl. Res., 2016, 8, 1748.
[8] Marzec-Kotarska B., Cybulski M., Kotarski J.C., Ronowicz A., Tarkowski R., Polak G., et al.: "Molecular bases of aberrant miR- 182 expression in ovarian cancer". Genes Chromosomes Cancer, 2016, 55, 877.
[9] Niu K., Shen W., Zhang Y., Zhao Y., Lu Y.: "MiR-205 promotes motility of ovarian cancer cells via targeting ZEB1". Gene, 2015, 574, 330.
[10] Wang L., Zhu M.J., Ren A.M., Wu H.F., Han W.M., Tan R.Y., Tu R.Q.: "A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer". PLoS One, 2014, 9, 96472.
[11] Wang Y.Q., Guo R.D., Guo R.M., Sheng W., Yin L.R.: "MicroRNA- 182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas". J. Cell. Biochem., 2013, 114, 1464.
[12] Zheng H., Zhang L.N., Zhao Y.R., Yang D., Song F.J., Wen Y., et al.: "Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.". PLoS One, 2013, 8, e77853.
[13] Xu J., Wu C., Che X., Wang L., Yu D., Zhang T., et al.: "Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis". Mol Carcinog, 2011, 50, 136.
[14] Zhu W., He J., Chen D., Zhang B., Xu L., Ma H., et al: "Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer". PloS one, 2014, 9, 87780.
[15] Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al: "Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases". Cell Res, 2008, 18, 997.
[16] Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al: "MicroRNA expression profiles classify human cancers". Nature, 2005, 435, 834.
[17] Eitan R., Kushnir M., Lithwick-Yanai G., David M.B., Hoshen M., Glezerman M., et al:"Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients". Gynecol Oncol, 2009, 114, 253.
[18] Sorrentino A., Liu C.G., Addario A., Peschle C., Scambia G., Ferlini C.:" Role of microRNAs in drug-resistant ovarian cancer cells". Gynecol Oncol, 2008, 111, 478.
[19] Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., et al: "MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer". Cancer Res, 2008, 68, 10307.
[20] Fang L., Du W.W., Yang W., Rutnam Z.J., Peng C., Li H., et al: "MiR-93 enhances angiogenesis and metastasis by targeting LATS2". Cell cycle, 2012, 11, 4352.
[21] Yang M., Chen J., Su F., Yu B., Su F., Lin L., et al.: "Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells". Mol. Cancer, 2011, 10, 117.
[22] Jacobs I., Bast R.C., Jr.: "The CA 125 tumour-associated antigen: a review of the literature". Hum. Reprod.,1989, 4, 1.
[23] Kirchhoff C.: "Molecular characterization of epididymal proteins". Rev. Reprod., 1998, 3, 86.
[24] Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A, Schummer M., McIntosh M., et al.: "The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma". Cancer Res., 2003, 63, 3695.
[25] Holcomb K., Vucetic Z., Miller M.C., Knapp R.C.: "Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women". Am. J. Obstet. Gynecol., 2011, 205, 351.
[1] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[2] Jae Hong Sang, Soo-Ho Chung. Is it enough in ovarian cancer staging surgery to laparoscopic surgery? Comparison of surgical methods[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 541-544.
[3] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[4] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[5] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
[6] F. Oyama, Y. Asano, H. Shimoda, K. Horie, J. Watanabe, Y. Yokoayama. Morphological analysis of peritoneal dissemination of ovarian cancer based on levels of carbonyl reductase 1 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 352-360.
[7] C.J. Heesterbeek, A.M. Thijs, R.H.M. Hermans, D. Boll, G.-J. Creemers. Bevacizumab in combination with metronomic oral cyclophosphamide: an effective and well-tolerated treatment for patients with recurrent ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 364-367.
[8] S.R Oh, J.-W. Park. Is the Risk of Malignancy Index a predictive tool for preoperative differentiation between borderline ovarian tumor and ovarian cancer?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 368-374.
[9] T. Shoji, E. Takatori, M. Kagabu, M. Futagami, Y. Yokoyama, H. Tokunaga, N. Yaegashi, T. Ohta, T. Watanabe, T Sugiyama. Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1 genotype in patients with recurrent ovarian cancer (TGCU 104 study)[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 380-385.
[10] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[11] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[12] L.D. Gutierrez-Castañeda, J.F. Polo, C. Carmona, D. Sanabria, D.M. Caballero, A. Jutinico, R. Parra-Medina. Expression of heat shock protein Hsp 27 in ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 221-226.
[13] K. Plagens–Rotman, M. Piskorz–Szymendera, B. PIĘTA. Lifestyle with particular emphasis on physical activity and genital carcinomas in women[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 233-239.
[14] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[15] X.W. Wang, J.W. Tian, L.L. Fan, R.H. Wang. The diagnostic value of color Doppler ultrasound on ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 273-276.
No Suggested Reading articles found!